Skip to main content
SpringerLink
Log in

Approach and Management of Cervical Cancer

  • Chapter
  • First Online:
International Manual of Oncology Practice

  • 770 Accesses

Abstract

Cervical cancer (CC) represents the third most commonly diagnosed cancer and the fourth cause of cancer death in women worldwide [GLOBOCAN: Estimated cancer incidence, mortality and prevalence worldwide in 2012 international agency for research on cancer; 2012. Available at: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Accessed 27 Dec 2017, 2012]. In 2012, across the world, 528,000 new cases were diagnosed with 266,000 deaths, with 85% of the cases occurring in developing countries (GLOBOCAN: Estimated cancer incidence, mortality and prevalence worldwide in 2012 international agency for research on cancer; 2012. Available at: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Accessed 27 Dec 2017, 2012; Mathers C, Boerma T, Ma Fat D: The global burden of disease: 2004 update. World Health Organization, Geneva, Available at: http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf. Accessed 27 Dec 2017, 2008; Kamangar F, Dores GM, Anderson WF: J Clin Oncol 24:2137–2150, 2006). In the United States, it is the third most common gynaecologic cancer diagnosed and cause of death among gynaecologic cancers (Siegel R, Naishadham D, Jemal A: CA Cancer J Clin 63:11, 2013). Human papillomavirus (HPV) is central to the development of cervical neoplasia and can be detected in 99.7% of CCs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. GLOBOCAN (2012) Estimated cancer incidence, mortality and prevalence worldwide in 2012 international agency for research on cancer; 2012. Available at: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Accessed 27 Dec 2017

  2. Mathers C, Boerma T, Ma Fat D (2008) The global burden of disease: 2004 update. World Health Organization, Geneva, Available at: http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf. Accessed 27 Dec 2017

  3. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137–2150

    Article  PubMed  Google Scholar 

  4. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11

    Article  PubMed  Google Scholar 

  5. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12

    Article  CAS  PubMed  Google Scholar 

  6. World Health Organization (2007) Cervical cancer, human papillomavirus (HPV), and HPV vaccines – key points for policy-makers and health professionals. http://www.who.int

  7. Quinn M, Babb P, Jones J, Allen E (1999) Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ 318(7188):904

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Shaw M, Galobardes B, Lawlor DA, Lynch J, Wheeler B, Davey Smith G (2007) The handbook of inequality and socioeconomic position: concepts and measures. The Policy Press, Bristol

    Book  Google Scholar 

  9. Vaccarella S, Laversanne M, Ferlay J, Bray F (2017 Nov 15) Cervical cancer in Africa, Latin America and the Caribbean and Asia: regional inequalities and changing trends. Int J Cancer 141(10):1997–2001

    Article  CAS  PubMed  Google Scholar 

  10. Rio de Janeiro (RJ) Instituto Nacional do Câncer Brasil. Estimativa 2012 Incidência do Câncer no Brasil. Available at: www.inca.gov.br/estimativa/2018. Accessed 25 Mar 2018

  11. Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, Matchar DB (2000) Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 132(10):810

    Article  CAS  PubMed  Google Scholar 

  12. Grisaru D, Covens A, Chapman B, Shaw P, Colgan T, Murphy J et al (2001) Does histology influence prognosis in patients with early-stage cervical carcinoma? Cancer 92(12):2999

    Article  CAS  PubMed  Google Scholar 

  13. International Collaboration of Epidemiological Studies of Cervical Cancer Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097

    Google Scholar 

  14. Bermudez A, Bhatla N, Leung E (2015) Cancer of the cervix uteri. Int J Gynaecol Obstet 131(Suppl 2):S88–S95

    Article  PubMed  Google Scholar 

  15. Hricak H, Gatsonis C, Chi DS, Amendola MA, Brandt K, Schwartz LH et al (2005) Role of imaging in pretreatment evaluation of early invasive cervical cancer: results of the intergroup study American College of Radiology Imaging Network 6651-Gynecologic Oncology Group 183. J Clin Oncol 23(36):9329–9337

    Article  PubMed  Google Scholar 

  16. Bipat S, Glas AS, van der Velden J, Zwinderman AH, Bossuyt PM, Stoker J (2003) Computed tomography and magnetic resonance imaging in staging of uterine cervical carcinoma: a systematic review. Gynecol Oncol 91(1):59–66

    Article  PubMed  Google Scholar 

  17. Hricak H, Yu KK (1996) Radiology in invasive cervical cancer. AJR Am J Roentgenol 167(5):1101–1108

    Article  CAS  PubMed  Google Scholar 

  18. Subak LL, Hricak H, Powell CB, Azizi L, Stern JL (1995) Cervical carcinoma: computed tomography and magnetic resonance imaging for preoperative staging. Obstet Gynecol 86(1):43–50

    Article  CAS  PubMed  Google Scholar 

  19. Grigsby PW, Siegel BA, Dehdashti F (2001) Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol 19(17):3745–3749

    Article  CAS  PubMed  Google Scholar 

  20. Rose PG, Adler LP, Rodriguez M, Faulhaber PF, Abdul-Karim FW, Miraldi F (1999) Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. J Clin Oncol 17(1):41–45

    Article  CAS  PubMed  Google Scholar 

  21. Hertel H, Kohler C, Elhawary T, Michels W, Possover M, Schneider A (2002) Laparoscopic staging compared with imaging techniques in the staging of advanced cervical cancer. Gynecol Oncol 87(1):46–51

    Article  PubMed  Google Scholar 

  22. Ramirez PT, Jhingran A, Macapinlac HA, Euscher ED, Munsell MF, Coleman RL et al (2011) Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer: a prospective correlation of surgical findings with positron emission tomography/computed tomography findings. Cancer 117(9):1928–1934

    Article  PubMed  Google Scholar 

  23. van de Lande J, Torrenga B, Raijmakers PG, Hoekstra OS, van Baal MW, Brolmann HA et al (2007) Sentinel lymph node detection in early stage uterine cervix carcinoma: a systematic review. Gynecol Oncol 106(3):604–613

    Article  PubMed  Google Scholar 

  24. Andikyan V, Khoury-Collado F, Denesopolis J, Park KJ, Hussein YR, Brown CL et al (2014) Cervical conization and sentinel lymph node mapping in the treatment of stage I cervical cancer: is less enough? Int J Gynecol Cancer 24(1):113–117

    Article  PubMed  PubMed Central  Google Scholar 

  25. Cormier B, Diaz JP, Shih K, Sampson RM, Sonoda Y, Park KJ et al (2011) Establishing a sentinel lymph node mapping algorithm for the treatment of early cervical cancer. Gynecol Oncol 122(2):275–280

    Article  PubMed  PubMed Central  Google Scholar 

  26. Lecuru F, Mathevet P, Querleu D, Leblanc E, Morice P, Darai E et al (2011) Bilateral negative sentinel nodes accurately predict absence of lymph node metastasis in early cervical cancer: results of the SENTICOL study. J Clin Oncol 29(13):1686–1691

    Article  PubMed  Google Scholar 

  27. Altgassen C, Hertel H, Brandstadt A, Kohler C, Durst M, Schneider A et al (2008) Multicenter validation study of the sentinel lymph node concept in cervical cancer: AGO Study Group. J Clin Oncol 26(18):2943–2951

    Article  PubMed  Google Scholar 

  28. Bats AS, Mathevet P, Buenerd A, Orliaguet I, Mery E, Zerdoud S et al (2013) The sentinel node technique detects unexpected drainage pathways and allows nodal ultrastaging in early cervical cancer: insights from the multicenter prospective SENTICOL study. Ann Surg Oncol 20(2):413–422

    Article  PubMed  Google Scholar 

  29. Cibula D, Abu-Rustum NR, Dusek L, Slama J, Zikan M, Zaal A et al (2012) Bilateral ultrastaging of sentinel lymph node in cervical cancer: lowering the false-negative rate and improving the detection of micrometastasis. Gynecol Oncol 127(3):462–466

    Article  PubMed  Google Scholar 

  30. Cibula D, Abu-Rustum NR, Dusek L, Zikan M, Zaal A, Sevcik L et al (2012) Prognostic significance of low volume sentinel lymph node disease in early-stage cervical cancer. Gynecol Oncol 124(3):496–501

    Article  CAS  PubMed  Google Scholar 

  31. Eiriksson LR, Covens A (2012) Sentinel lymph node mapping in cervical cancer: the future? BJOG 119(2):129–133

    Article  CAS  PubMed  Google Scholar 

  32. Wu Y, Li Z, Wu H, Yu J (2013) Sentinel lymph node biopsy in cervical cancer: a meta-analysis. Mol Clin Oncol 1(6):1025–1030

    Article  PubMed  PubMed Central  Google Scholar 

  33. Kadkhodayan S, Hasanzadeh M, Treglia G, Azad A, Yousefi Z, Zarifmahmoudi L et al (2015) Sentinel node biopsy for lymph nodal staging of uterine cervix cancer: a systematic review and meta-analysis of the pertinent literature. Eur J Surg Oncol 41(1):1–20

    Article  CAS  PubMed  Google Scholar 

  34. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S (2007) Human papilloma- virus and cervical cancer. Lancet 370(9590):89

    Article  CAS  Google Scholar 

  35. Wolf JK, Ramirez PT (2001) The molecular biology of cervical cancer. Cancer Investig 19:621–629

    Article  CAS  Google Scholar 

  36. zur Hausen H (1999) Papillomaviruses in human cancers. Proc Assoc Am Phys 111:581–587

    Article  CAS  PubMed  Google Scholar 

  37. Doorbar J (2005) The papillomavirus life cycle. J Clin Virol 32(suppl 1):S7–S15

    Article  CAS  PubMed  Google Scholar 

  38. Scheuer ME, Tortolero-Luna G, Adler-Storthz K (2005) Human papillomavirus infection: biology, epidemiology, and prevention. Int J Gynecol Cancer 15:727–746

    Article  Google Scholar 

  39. Martin CM, Astbury K, O’Leary JJ (2006) Molecular profiling of cervical neoplasia. Expert Rev Mol Diagn 6(2):217–229

    Article  CAS  PubMed  Google Scholar 

  40. Santin AD, Sill MW, McMeekin DS, Leitao MM, Jr Brown J, Sutton GP, Van Le L, Griffin P, Boardman CH (2011) Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 122:495–500

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Zhang HS, Wang RJ, Fu QF, Gao S, Sun BT, Sun H, Ma QJ (2014) Diagnostic value of thyroglobulin measurement with fine-needle aspiration biopsy for lymph node metastases in patients with a history of differentiated thyroid cancer. Asian Pac J Cancer Prev 15(24):10905–10909

    Article  PubMed  Google Scholar 

  42. Klaes R, Benner A, Friedrich T, Ridder R, Herrington S, Jenkins D, Kurman RJ, Schmidt D, Stoler M, von Knebel Doeberitz M (2002) p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol 26(11):1389–1399

    Article  PubMed  Google Scholar 

  43. Lee JS, Kim HS, Park JT (2003) Expression of vascular endothelial growth factor in the progression of cervical neoplasia and its relation to angiogenesis and p53 status. Anal Quant Cytol Histol 25:11–303

    Google Scholar 

  44. Jansen-Dürr P (1996) How viral oncogenes make the cell cycle. Trends Genet 12(7):270–275. Review

    Article  PubMed  Google Scholar 

  45. Cerciello F, Riesterer O, Sherweif M, Odermatt B, Ciernik IF (2007) Is EGFR a moving target during radiotherapy of carcinoma of the uterine cervix? Gynecol Oncol 106(2):9–394

    Article  CAS  Google Scholar 

  46. Fuchs I, Vorsteher N, Bühler H (2007) The prognostic significance of human epidermal growth factor receptor correlations in squamous cell cervical carcinoma. Anticancer Res 27(2):63–959

    Google Scholar 

  47. Arias PH, Joste N, Chavez A (2008) Absence of epidermal growth receptor mutations in cervical cancer. Int J Gynecol Cancer 18:54–749

    Google Scholar 

  48. Marzano R, Corrado G, Merola R (2004) Analysis of chromosomes 3, 7, X and the EGFR gene inuterine cervical cancer progression. Eur J Cancer 40:9–1624

    Article  CAS  Google Scholar 

  49. Bellone S, Palmieri M, Gokden M, Joshua J, Roman JJ, Pecorelli S, Cannon MJ, Santin AD (2003) Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy. Gynecol Oncol 91(1):231–240

    Article  CAS  PubMed  Google Scholar 

  50. Contreras PA, De la Cruz HE, Martínez RI, Dueñas GA, Lizano M (2009) E6 variants of human papillomavirus 18 differentially modulate the protein kinase B/phosphatidylinositol 3-kinase (AKT/PI3K) signaling pathway. Virology 383:78–85

    Article  CAS  Google Scholar 

  51. Charette ST, McCance DJ (2007) The E7 protein from human papillomavirus type 16 enhances keratinocyte migration in an AKT-dependent manner. Oncogene 52:7386–7390

    Article  CAS  Google Scholar 

  52. Bertelsen BI, Steine SJ, Sandvei R (2006) Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PI3KCA amplification and AKT phosphorylation. Int J Cancer 118:1877–1883

    Article  CAS  PubMed  Google Scholar 

  53. Cheung TH, Lo KW, Yim SF, Chan LK, Heung MS, Chan CS, Cheung AY, Chung TK, Wong YF (2004) Epigenetic and genetic alternation of PTEN in cervical neoplasm. Gynecol Oncol 93(3):621–627

    Article  CAS  PubMed  Google Scholar 

  54. Janku F, Wheler J, Westin S et al (2012 Mar 10) PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 30(8):777–782

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Chen YJ (2007) Targetes mTOR in human gynecological cancers. J Cancer Mol 3(4):6–101

    Google Scholar 

  56. Fothergill T, McMillan NA (2006) Papillomavirus virus-like particles activate the PI3-kinase pathway via alpha-6 beta-4 integrin upon binding. Virology 352(2):319–328

    Article  CAS  PubMed  Google Scholar 

  57. Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3(6):401–410. Review

    Article  CAS  PubMed  Google Scholar 

  58. Bodily JM, Mehta KP, Laimins LA (2011) Human papillomavirus E7 enhances hypoxia-inducible factor 1-mediatedtranscriptional binding of histone deacetylases. Cancer Res 71:1187–1195

    Article  CAS  PubMed  Google Scholar 

  59. Cheng WF, Chen CA, Lee CN (1999) Vascular endothelial growth factor in cervical carcinoma. Obstet Gynecol 93:5–761

    Google Scholar 

  60. Richart RM (1973) Cervical intraepithelial neoplasia. In: Pathology annual, vol 8. Appleton-Century-Crofts, East Norwalk, p 301

    Google Scholar 

  61. Crum CP (2003) Should the Bethesda system terminology be used in diagnostic surgical pathology?: Point. Int J Gynecol Pathol 22:5

    Article  PubMed  Google Scholar 

  62. Schneider V (2003) Should the Bethesda system terminology be used in diagnostic surgical pathology?: Counterpoint. Int J Gynecol Pathol 22:13

    Article  PubMed  Google Scholar 

  63. DeVitaJr VT, Hellman S, Rosenberg SA (2011) Cancer – principles & practice of oncology, vol 1/1, 9th edn. Lippincott Williams & Wilkins, Baltimore

    Google Scholar 

  64. Manos MM, Kinney WK, Hurley LB et al (1999) Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 281:1605

    Article  CAS  PubMed  Google Scholar 

  65. Ries LAG, Melbert D, Krapcho M et al (2007) SEER cancer statistics review, 1975–2004. National Cancer Institute, Bethesda

    Google Scholar 

  66. Eifel PJ, Burke TW, Morris M, Smith TL (1995) Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol 59:38

    Article  CAS  PubMed  Google Scholar 

  67. Smith HO, Tiffany MF, Qualls CR, Key CR (2000) The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States – a 24-year population-based study. Gynecol Oncol 78:97

    Article  CAS  PubMed  Google Scholar 

  68. Albores-Saavedra J, Gersell D, Gilks CB, Henson DE, Lindberg G, Santiago H, Scully RE, Silva E, Sobin LH, Tavassoli FJ, Travis WD, Woodruff JM (1997) Terminology of endocrine tumors of the uterine cervix: results of a workshop sponsored by the College of American Pathologists and the National Cancer Institute. Arch Pathol Lab Med 121:34

    CAS  PubMed  Google Scholar 

  69. Villella JA, Bogner PN, Jani-Sait SN, Jani-Sait SN, Block AM, Lele S (2005) Rhabdomyosarcoma of the cervix in sisters with review of the literature. Gynecol Oncol 99:742

    Article  PubMed  Google Scholar 

  70. Kendrick JE 4th, Straughn JM Jr (2005) Two cases of non-Hodgkin’s lymphoma presenting as primary gynecologic malignancies. Gynecol Oncol 98:490

    Article  PubMed  Google Scholar 

  71. Wright JD, Rosenblum K, Huettner PC, Mutch DG, Rader JS, Powell MA, Gibb RK (2005) Cervical sarcomas: an analysis of incidence and outcome. Gynecol Oncol 99:348

    Article  PubMed  Google Scholar 

  72. Azodi M, Chambers SK, Rutherford TJ, Kohorn EI, Schwartz PE, Chambers JT (1999) Adenocarcinoma in situ of the cervix: management and outcome. Gynecol Oncol 73:348

    Article  CAS  PubMed  Google Scholar 

  73. Kostopoulou E, Keating JT, Crum CP (2001) Pathology. In: Eifel PJ, Levenback C (eds) Cancer of the female lower genital tract. B C Decker, Inc, London, p 9

    Google Scholar 

  74. Bean SM, Kurtycz DFI, Colgan TJ (2011) Recent developments in defining microinvasive and early invasive carcinoma of the uterine cervix. J Lower Genital Tract Dis 15:146–157

    Article  Google Scholar 

  75. Kristensen GB, Abeler VM, Risberg B et al (1999) Tumor size, depth of invasion and grading of the invasive tumor front are the main prognostic factors in early squamous cell cervical carcinoma. Gynecol Oncol 74:245–251

    Article  CAS  PubMed  Google Scholar 

  76. Young RH, Clement PB (2002) Endocervical adenocarcinoma and its variants: their mor- phology and differential diagnosis. Histopathology 41:185–207

    Article  CAS  PubMed  Google Scholar 

  77. Gien LT, Beauchemin MC, Thomas G (2010) Adenocarcinoma: a unique cervical cancer. Gynecol Oncol 116:140–146

    Article  CAS  PubMed  Google Scholar 

  78. Pirog EC, Kleter B, Olgac S et al (2000) Prevalence of human papillomavirus DNA in differ- ent histological subtypes of cervical adenocarcinoma. Am J Pathol 157:1055–1062

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Barakat RR, Berchuck A, Markman M, Randall ME (2013) Principles and practice of gyne- cologic oncology, 6th edn. Lippincott Williams & Wilkins, Philadelphia

    Google Scholar 

  80. An HJ, Kim KR, Kim IS et al (2005) Prevalence of human papillomavirus DNA in various histological subtypes of cervical adenocarcinoma: a population-based study. Mod Pathol 18:528–534

    Article  CAS  PubMed  Google Scholar 

  81. Wang SS, Sherman ME, Silverberg SG, Carreon JD, Lacey JV Jr, Zaino R, Kurman RJ, Hildesheim A (2006) Pathological characteristics of cervical adenocarcinoma in a multi- center U.S.-based study. Gynecol Oncol 103:541–546

    Article  PubMed  Google Scholar 

  82. Viswanathan AN, Deavers MT, Jhingran A, Ramirez PT, Levenback C, Eifel PJ (2004) Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence. Gynecol Oncol 93:27

    Article  CAS  PubMed  Google Scholar 

  83. Landoni F, Maneo A, Colombo A, Placa F, Favini G, Ferri L, Mangioni C (1997) Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 350(9077):535–540

    Article  CAS  PubMed  Google Scholar 

  84. Elliott P, Coppleson M, Rusell P, Liouros P, Carter J, Macleod C, Jones M (2000) Early invasive (FIGO stage IA) carcinoma of the cervix: a clinicopathologic study of 476 cases. Int J Gynecol Cancer 10(1):42–45

    Article  PubMed  Google Scholar 

  85. Morris M, Mitchell MF, Silva EG, Copeland LJ, Gershenson DM (1993) Cervical conization as definitive therapy for early invasive squamous carcinoma of the cervix. Gynecol Oncol 51(2):193–196

    Article  CAS  PubMed  Google Scholar 

  86. Piver MS, Rutledge F, Smith JP (1994) Five classes of extended hysterectomy for women with cervical cancer. Obstet Gynecol 44(2):265–272

    Google Scholar 

  87. Querleu D, Morrow CP, Cibula D, Abu-Rustum NR, Benedetti-Panici P, Köhler C, Raspagliesi F (2011) New classification system of radical hysterectomy: emphasis on a three-dimensional anatomic template for parametrial resection. Gynecol Oncol 122(2):264–268

    Article  PubMed  Google Scholar 

  88. Maiman MA, Fruchter RG, DiMaio TM, Boyce JG (1998) Superficially invasive squamous cell carcinoma of the cervix. Obstet Gynecol 72(4):399–403

    Google Scholar 

  89. Dargent D, Martin X, Sacchetoni A, Mathevet P (2000) Laparoscopic vaginal radical trach- electomy: a treatment to preserve the fertility of cervical carcinoma patients. Cancer 88(8):1877–1882

    Article  CAS  PubMed  Google Scholar 

  90. Mangler M, Lanowska M, Köhler C, Vercellino F, Schneider A, Speiser D (2014) Pattern of cancer recurrence in 320 patients after radical vaginal trachelectomy. Int J Gynecol Cancer 24(1):130–134

    Article  PubMed  Google Scholar 

  91. Kolomainen DF, Bradley RJ, Larsen-Disney P, Shepherd JH (2013) Radical vaginal trachelectomy at 16 weeks’ gestation: a case report. Gynecol Oncol Case Rep 14(5):28–30

    Article  Google Scholar 

  92. Lanowska M, Mangler M, Speiser D, Bockholdt C, Schneider A, Köhler C, Vasiljeva J, Al-Hakeem M, Vercellino GF (2014) Radical vaginal trachelectomy after laparoscopic staging and neoadjuvant chemotherapy in women with early-stage cervical cancer over 2 cm: oncologic, fertility, and neonatal outcome in a series of 20 patients. Int J Gynecol Cancer 24(3):586–593

    Article  PubMed  Google Scholar 

  93. Querleu D (1991) Radical hysterectomies by the Schauta-Amreich and Schauta-Stoeckel techniques assisted by celioscopy. J Gynecol Obstet Biol Reprod (Paris) 20(5):747–748

    CAS  Google Scholar 

  94. Kucukmetin A, Biliatis I, Naik R, Bryant A (2013) Laparoscopically assisted radical vaginal hysterectomy versus radical abdominal hysterectomy for the treatment of early cervical cancer. Cochrane Database Syst Rev 10:CD006651

    Google Scholar 

  95. Pergialiotis V, Rodolakis A, Christakis D, Thomakos N, Vlachos G, Antsaklis A (2013) Laparoscopically assisted vaginal radical hysterectomy: systematic review of the literature. J Minim Invasive Gynecol 20(6):745–753

    Article  PubMed  Google Scholar 

  96. Lowe MP, Chamberlain DH, Kamelle SA, Johnson PR, Tillmanns TD (2009) A multi- institutional experience with robotic-assisted radical hysterectomy for early stage cervical cancer. Gynecol Oncol 113(2):191–194

    Article  PubMed  Google Scholar 

  97. GilIbáñez B, Díaz-Feijoo B, Pérez-Benavente A, Puig-Puig O, Franco-Camps S, Centeno C, Xercavins J, Gil-Moreno A (2013) Nerve sparing technique in robotic-assisted radical hysterectomy: results. Int J Med Robot 9(3):339–344

    Article  Google Scholar 

  98. Yim GW, Kim SW, Nam EJ, Kim S, Kim YT (2013) Learning curve analysis of robot-assisted radical hysterectomy for cervical cancer: initial experience at a single institution. J Gynecol Oncol 24(4):303–312

    Article  PubMed  PubMed Central  Google Scholar 

  99. Tinelli R, Malzoni M, Cosentino F, Perone C, Fusco A, Cicinelli E, Nezhat F (2011) Robotics versus laparoscopic radical hysterectomy with lymphadenectomy in patients with early cervical cancer: a multicenter study. Ann Surg Oncol 18(9):2622–2628

    Article  PubMed  Google Scholar 

  100. Rotman M, Sedlis A, Piedmonte MR, Bundy B, Lentz SS, Muderspach LI, Zaino RJ (2006) A phase III randomized trial of postoperative pelvic irradiation in stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys 65(1):169–176

    Article  PubMed  Google Scholar 

  101. Landoni F, Maneo A, Cormio G, Perego P, Milani F, Caruso O, Mangioni C (2011) Class II versus class III radical hysterectomy in stage IB-IIA cervical cancer: a propective randomized study. Gynecol Oncol 80(1):3–12

    Article  Google Scholar 

  102. Richard SD, Krivak TC, Castleberry A, Beriwal S, Kelley JL 3rd, Edwards RP, Sukumvanich P (2008) Survival for stage IB cervical cancer with positive lymph node involvement: a comparison of completed vs. abandoned radical hysterectomy. Gynecol Oncol 109(1):43–48

    Article  PubMed  Google Scholar 

  103. Whitney CW, Sause W, Bundy BN et al (1999) A randomized comparison of fl uorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB- IVA carcinoma of the cervix with negative para-aortic lymph nodes. A gynecologic oncology group and southwest oncology group study. J Clin Oncol 17:1339–1348

    Article  CAS  PubMed  Google Scholar 

  104. Rose PG, Bundy BN, Watkins EB et al (1999) Concurrent cisplatin-based chemoradiation improves progression free and overall survival in advanced cervical cancer. Results of a randomized gynecologic oncology group study. N Engl J Med 340:1144–1153

    Article  CAS  PubMed  Google Scholar 

  105. Morris M, Eifel PJ, Lu J et al (1999) Pelvic radiation with concurrent chemotherapy versus pelvic and para-aortic radiation for high-risk cervical cancer: a randomized radiation therapy oncology group clinical trial. N Engl Med 340:1137–1143

    Article  CAS  Google Scholar 

  106. Finlay MH, Ackerman I, Tirona RG, Hamilton P, Barbera L, Thomas G (2006) Use of CT stimulation for treatment of cervical cancer to assess the adequacy of limph node coverage of conventional pelvic fi elds based on bony landmarks. Int J Radiat Oncol Biol Phys 64:205–209

    Article  PubMed  Google Scholar 

  107. Lim K, Small W Jr, Portelance L et al (2011) Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer. Int J Radiat Oncol Biol Phys 79(2):348–355

    Article  PubMed  Google Scholar 

  108. Wolfson AH, Abdel-Wahab M, Markoe AM et al (1997) A quantitative assessment of standard vs. customized midline shield construction for invasive cervical carcinoma. Int J Radiat Oncol Biol Phys 37:237–242

    Article  CAS  PubMed  Google Scholar 

  109. Rajasooriyar C, Van Dyk S, Lindawati M, Bernshaw D, Kondalsamy-Chennakesavan S, Narayan K (2012) Reviewing the role of parametrial boost in patients with cervical cancer with clinically involved parametria and staged with positron emission tomography. Int J Gynecol Cancer 22(9):1532–1537

    PubMed  Google Scholar 

  110. Vargo JA, Kim H, Choi S, Sukumvanich P, Olawaiye AB, Kelley JL, Edwards RP, Comerci JT, Beriwal S (2014) Extended field intensity modulated radiation therapy with concomitant boost for lymph node-positive cervical cancer: analysis of regional control and recurrence patterns in the positron emission tomography/computed tomography era. Int J Radiat Oncol Biol Phys 90:1091–1098

    Article  PubMed  Google Scholar 

  111. Kim YJ, Kim JY, Yoo SH, Min BJ, Chung KZ, Seo SS, Kang SB, Lim MC, Hwang JH, Yoo HJ, Park SY (2013) High control rate for lymph nodes in cervical cancer treated with high-dose radiotherapy using helical tomotherapy. Technol Cancer Res Treat 12:45–51

    Article  CAS  PubMed  Google Scholar 

  112. Herrera FG, Prior JO (2013) The role of PET/CT in cervical cancer. Front Oncol 3:34

    Article  PubMed  PubMed Central  Google Scholar 

  113. Gandhi AK, Sharma DN, Rath GK et al (2013) Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: a prospective randomized study. Int J Radiat Oncol Biol Phys 87(3):542–548

    Article  PubMed  Google Scholar 

  114. Klopp AH, Moughan J, Portelance L, Miller BE, Salehpour MR, Hildebrandt E, Nuanjing J, D’Souza D, Souhami L, Small W Jr, Gaur R, Jhingran A (2013) Hematologic toxicitiy in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer. Int J Radiat Oncol Biol Phys 86(1):83–90

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Beriwal S, Gan GN, Heron DE et al (2007) Early clinical outcome with concurrent chemotherapy and extended-field, intensitymodulated radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys 68:166–171

    Article  PubMed  Google Scholar 

  116. Renard-Oldrini S, Brunaud C, Huger S, Marchesi V, Tournier-Rangeard L, Bouzid D, Harter V, Peiffert D (2012) Dosimetric comparison between the instensity modulated radiotherapy with fixed field and rapid arc of cervix cancer. Cancer Radiother 16(3):209–214

    Article  CAS  PubMed  Google Scholar 

  117. Wang W, Meng Q, Hou X et al (2017) Efficacy and toxicity of image-guided intensity-modulated radiation therapy combined with dose-escalated brachytherapy for stage IIB cervical cancer. Oncotarget 8(61):102965–102973

    PubMed  PubMed Central  Google Scholar 

  118. Lanciano RM, Martz K, Coia LR, Hanks GE (1991) Tumor and treatment factors improving outcome in stage III-B cervix cancer. Int J Radiat Oncol Biol Phys 1:95–100

    Article  Google Scholar 

  119. Hong JC, Foote J, Broadwater G et al (2017) Data-derived treatment duration goal for cervical cancer: should 8 weeks remain the target in the era of concurrent chemoradiation? JCO Clin Cancer Inform 1:1–15

    Article  PubMed  Google Scholar 

  120. Dimopoulos JC et al (2009) MRI assessment of cervical cancer for adaptive radiotherapy. Strahlenther Onkol 85(5):282–287

    Article  Google Scholar 

  121. Patel FD, Sharma SC, Negi PS, Ghoshal S, Gupta BD (1994) Low dose rate vc. High dose rate brachytherapy in the treatment of carcinoma of the uterine cervix: a clinical trial. Int J Radiat Oncol Biol Phys 28:335–341

    Article  CAS  PubMed  Google Scholar 

  122. Huerta Bahena J, Almendaro SL, Arroyo HC, Trejo MB (2008) Three fraction high dose rate brachytherapy schedule for treatment of locally advanced uterine cervix cancer center: clinical results, emphasis in dosimetric parameters and morbidity. Cancerología 3:105–110

    Google Scholar 

  123. Viswanathan AN, Beriwal S, De Los Santos J (2012) The American brachytherapy society treatment recommendations for locally advanced carcinoma of the cervix part II: high dose-rate brachytherapy. Brachytherapy 11(1):47–52

    Article  PubMed  PubMed Central  Google Scholar 

  124. ICRU (2016) Report 89, prescribing, recording, and reporting brachytherapy for cancer of the cervix. J Int Commission Radiat Units Meas 13, Pages NP

    Google Scholar 

  125. Abdel-Wahab et al (2017) Analysis of outcomes using external beam radiotherapy plus high dose rate brachytherapy (4×7 Gy or 2×9 Gy) for cervix cancer in a multi-institution trial, Plenary Session at ASTRO’s 59th Annual Meeting, San Diego

    Google Scholar 

  126. Choy D, Wong LC, Sham J, Ngan HYS, Ma HK (1993) Dose tumor response for carcinoma of cervix: an analysis of 594 patients treated by radiotherapy. Gynecol Oncol 49:311–317

    Article  CAS  PubMed  Google Scholar 

  127. Viswanathan AN, Thomadsen B (2012) American Brachytherapy Society Cervical Cancer Recommendations Committee; American Brachytherapy Society. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part I: general principles. Brachytherapy 11(1):33–46

    Article  PubMed  Google Scholar 

  128. Rijkmans EC, Nout RA, Rutten IH (2014) Improved survival of patients with cervical cancer treated with image-guided brachytherapycompared with conventional brachytherapy. Gynecol Oncol 135(2):231–238

    Article  CAS  PubMed  Google Scholar 

  129. Pötter R, Georg P, Dimopoulos J et al (2011) Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiother Oncol 100:116–123

    Article  PubMed  PubMed Central  Google Scholar 

  130. Mahmoud O, Kilic S, Khan AJ, Beriwal S, Small W Jr (2017) External beam techniques to boost cervical cancer when brachytherapy is not an option—theories and applications. Ann Transl Med 5(10):207

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  131. Han K, Milosevic M, Fyles A, Pintilie M, Viswanathan AN (2013) Trends in the utilization of brachytherapy in cervical cancer in the United States. Int J Radiat Oncol Biol Phys 87(1):111–119

    Article  PubMed  Google Scholar 

  132. Delgado G, Bundy B, Zaino R, Sevin BU, Creasman WT, Major F (1990) Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 38:352

    Article  CAS  PubMed  Google Scholar 

  133. Levine DA et al (2010) Principles and practice of gynecologic oncology (ed1). Lippincott Williams & Wilkins, Philadelphia

    Google Scholar 

  134. Choy D, Wong LC, Sham J, Ngan HY, Ma HK (1993) Dose-tumor response of carcinoma of cervix: an analysis of 594 patients treated by radiotherapy. Gynecol Oncol 49(3):311–317

    Article  CAS  PubMed  Google Scholar 

  135. Rydzewska L, Tierney J, Vale CL, Symonds PR (2012) Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev 12:CD007406

    PubMed  Google Scholar 

  136. Peters WA III, Liu PY, Barrett RJ et al (1999) Cisplatin and 5-fluorouracil plus radiation therapy are superior to radiation therapy as adjunctive in high-risk early stage carcinoma of the cervicix after radical hysterectomy and pelvic lymphadenectomy: report of a phase III intergroup study. Gynecol Oncol 72:443

    Article  Google Scholar 

  137. Pearcey R, Brundage M, Drouin P, Jeffrey J, Johnston D, Lukka H, MacLean G, Souhami L, Stuart G, Tu D (2002) Phase III trial comparing radical radiotherapy with and without cisplatin chemoterapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol 20:966–972

    Article  CAS  PubMed  Google Scholar 

  138. Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration CCCMAC (2010) Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database Syst Rev 1:CD008285

    Google Scholar 

  139. Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, Benda J, Cella D (2009) Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a gynecologic oncology group study. J Clin Oncol 27:4649–4655

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  140. Dueñas-González A, Zarbá JJ, Patel F, Alcedo JC, Beslija S, Casanova L, Pattaranutaporn P, Hameed S, Blair JM, Barraclough H, Orlando M (2011) Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIb to IVa carcinoma of the cervix. J Clin Oncol 29:1678–1685

    Article  CAS  PubMed  Google Scholar 

  141. Wang N, Guan QL, Wang K, Zhou X, Gao C, Yang HT et al (2011) Radiochemotherapy versus radiotherapy in locally advanced cervical cancer: a meta-analysis. Arch Gynecol Obstet 283(1):103–108

    Article  CAS  PubMed  Google Scholar 

  142. Quinn MA, Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, Heintz AP, Ngan HY, Pecorelli S (2006) Carcinoma of the cervix uteri. Int J Gynaecol Obstet 95(Suppl 1):S43, FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer

    Google Scholar 

  143. Lim MC, Lee HS, Seo SS, Kim MS, Kim JY, Zo JI, Park SY (2010) Pathologic diagnosis and resection of suspicious thoracic metastases in patients with cervical cancer through thora- cotomy or video-assisted thoracic surgery. Gynecol Oncol 116:478

    Article  PubMed  Google Scholar 

  144. Patel CN, Nazir SA, Khan Z, Gleeson FV, Bradley KM (2011) 18F-FDG PET/CT of cervical carcinoma. AJR Am J Roentgenol 196:1225

    Article  PubMed  Google Scholar 

  145. Pallardy A, Bodet-Milin C, Oudoux A, Campion L, Bourbouloux E, Sagan C, Ansquer C, Testard A, Resche I, Bridji B, Kraeber-Bodéré F, Rousseau C (2010) Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma. Eur J Nucl Med Mol Imaging 37:1270

    Article  PubMed  Google Scholar 

  146. Friedlander M, Grogan M (2002) U.S. Preventative services task force. Guidelines for the treatment of recurrent and metastatic cervical cancer. Oncologist 7:342

    PubMed  Google Scholar 

  147. Berek JS, Howe C, Lagasse LD, Hacker NF (2005) Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA. Gynecol Oncol 99:153

    Article  PubMed  Google Scholar 

  148. Rutledge S, Carey MS, Prichard H, Allen HH, Kocha W, Kirk ME (1994) Conservative surgery for recurrent or persistent carcinoma of the cervix following irradiation: is exenteration always necessary? Gynecol Oncol 52:353

    Article  CAS  PubMed  Google Scholar 

  149. Mahé MA, Gérard JP, Dubois JB, Roussel A, Bussières E, Delannes M, Guillemin F, Schmitt T, Dargent D, Guillard Y, Martel P, Richaud P, Cuillière JC, De Ranieri J, Malissard L (1996) Intraoperative radiation therapy in recurrent carcinoma of the uterine cervix: report of the French Intraoperative Group on 70 patients. Int J Radiat Oncol Biol Phys 34:21

    Article  PubMed  Google Scholar 

  150. Wang CJ, Lai CH, Huang HJ, Hong JH, Chou HH, Huang KG, Lin JD (1999) Recurrent cervical carcinoma after primary radical surgery. Am J Obstet Gynecol 181:518

    Article  CAS  PubMed  Google Scholar 

  151. Haasbeek CJ, Uitterhoeve AL, van der Velden J, González DG, Stalpers LJ (2008) Long-term results of salvage radiotherapy for the treatment of recurrent cervical carcinoma after prior surgery. Radiother Oncol 89:197

    Article  PubMed  Google Scholar 

  152. Hong JH, Tsai CS, Lai CH, Chang TC, Wang CC, Chou HH, Lee SP, Hsueh S (2004) Recurrent squamous cell carcinoma of cervix after definitive radiotherapy. Int J Radiat Oncol Biol Phys 60:249

    Article  PubMed  Google Scholar 

  153. Long HJ 3rd. (2007) Management of metastatic cervical cancer: review of the literature. J Clin Oncol 25:2966

    Article  CAS  PubMed  Google Scholar 

  154. Movva S, Rodriguez L, Arias-Pulido H, Verschraegen C (2009) Novel chemotherapy approaches for cervical cancer. Cancer 115:3166

    Article  CAS  PubMed  Google Scholar 

  155. Garces ÁH, Mora PA, Alves FV, do Carmo CC, Grazziotin R, Fernandes AC, Nogueira-Rodrigues A, de Melo AC (2013) First-line paclitaxel and carboplatin in persistent/recurrent or advanced cervical cancer: a retrospective analysis of patients treated at Brazilian National Cancer Institute. Int J Gynecol Cancer 23(4):743–748

    Article  PubMed  Google Scholar 

  156. Lhomme C, Fumoleau P, Fargeot P, Krakowski Y, Dieras V, Chauvergne J, Vennin P, Rebattu P, Roche H, Misset JL, Lentz MA, Van Glabbeke M, Matthieu-Boué A, Mignard D, Chevallier B (1999) Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recur- rent squamous cell carcinoma of the cervix. J Clin Oncol 17:3142–3142

    Article  Google Scholar 

  157. Brader KR, Morris M, Levenback C, Levy L, Lucas KR, Gershenson DM (1998) Chemotherapy for cervical carcinoma: factors determining response and implications for clinical trial design. J Clin Oncol 16:1879

    Article  CAS  PubMed  Google Scholar 

  158. Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, Miller DS, Olt G, King S, Boggess JF, Rocereto TF (2004) Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 22:3113

    Article  CAS  PubMed  Google Scholar 

  159. Long HJ III, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV (2005) Gynecologic Oncology Group Study. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a gynecologic oncology group study. J Clin Oncol 23:4626

    Article  CAS  PubMed  Google Scholar 

  160. Tanioka M, Katsumata N, Yonemori K, Kouno T, Shimizu C, Tamura K, Ando M, Fujiwara Y (2011) Second platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy. Cancer Chemother Pharmacol 68:337–342

    Article  CAS  PubMed  Google Scholar 

  161. Tewari KS, Sill M, Long HJ et al (2013) Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. J Clin Oncol 31:abstr 3

    Article  Google Scholar 

  162. Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, DiSaia PJ, Copeland LJ, Creasman WT, Stehman FB, Brady MF, Burger RA, Thigpen JT, Birrer MJ, Waggoner SE, Moore DH, Look KY, Koh WJ, Monk BJ (2017) Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 390(10103):1654

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  163. Kitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, Nakanishi T, Nishimura S, Ushijima K, Takano M, Satoh T, Yoshikawa H (2015) Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol 33(19):2129–2135

    Article  CAS  PubMed  Google Scholar 

  164. Frenel JS, Le Tourneau C, O’Neil B, Ott PA, Piha-Paul SA, Gomez-Roca C et al (2017) Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial. J Clin Oncol 35(36):4035

    Article  CAS  PubMed  Google Scholar 

  165. Weiss GR, Green S, Hannigan EV, Boutselis JG, Surwit EA, Wallace DL, Alberts DS (1990) A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a southwest oncology group study. Gynecol Oncol 39:332

    Article  CAS  PubMed  Google Scholar 

  166. Alberts DS, Blessing JA, Landrum LM, Warshal DP, Martin LP, Rose SL, Bonebrake AJ, Ramondetta LM (2012) Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: a gynecologic oncology group study. Gynecol Oncol 127:451

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  167. Muggia FM, Blessing JA, Method M, Miller DS, Johnson GA, Lee RB, Menzin A (2004) Gynecologic oncology group study. Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 92:639

    Article  CAS  PubMed  Google Scholar 

  168. Curtin JP, Blessing JA, Webster KD, Rose PG, Mayer AR, Fowler WC Jr, Malfetano JH, Alvarez RD (2001) Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a gynecologic oncology group study. J Clin Oncol 19:1275

    Article  CAS  PubMed  Google Scholar 

  169. Lorusso D, Ferrandina G, Pignata S, Ludovisi M, Viganò R, Scalone S, Scollo P, Breda E, Pietragalla A, Scambia G (2010) Evaluation of pemetrexed (Alimta, LY231514) as second- line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. Ann Oncol 21:61

    Article  CAS  PubMed  Google Scholar 

  170. Thigpen T (2003) The role of chemotherapy in the management of carcinoma of the cervix. Cancer J 9:425

    Article  CAS  PubMed  Google Scholar 

  171. Muderspach LI, Blessing JA, Levenback C, Moore JL Jr (2001) A phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 81:213

    Article  CAS  PubMed  Google Scholar 

  172. Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE, Roman LD (2009) Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 27:1069–1074

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  173. Monk BJ, Mas Lopwz L, Zarba JJ, Oaknin A, Tarpin C, Termrungruanglert W, Alber JA, Ding J, Stutts MW, Pandite LN (2010) Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol 28:3562–3569

    Article  CAS  PubMed  Google Scholar 

  174. Santin AD, Sill MW, McKeekin DS, Leitao MM Jr, Brown J, Sutton GP, Van Le L, Griffin P, Boardman CH (2011) Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a gynecologic oncology group study. Glob Open 122(3):495–500

    CAS  Google Scholar 

  175. Advisory Committee on Immunization Practices (2013) Recommended adult immunization schedule: United States, 2013. Ann Intern Med 158:191

    Article  Google Scholar 

  176. Massad LS, Schneider M, Watts H et al (2001) Correlating papanicolaou smear, colposcopic impression, and biopsy: results from the Women’s interagency HIV study. J Low Genit Tract Dis 5:212

    CAS  PubMed  Google Scholar 

  177. Garland SM, Hernandez-Avila M, Wheeler CM, Darragh T, Abulafia O, Salzer E, Muderspach LI, Sidawy M, Melnick S (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356:1928

    Article  CAS  PubMed  Google Scholar 

  178. FUTURE II Study Group (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356:1915

    Article  Google Scholar 

  179. Paavonen J, Naud P, Salmerón J et al (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374:301

    Article  CAS  PubMed  Google Scholar 

  180. National Center for Immunization and Respiratory Diseases (2011) General recommendations on immunization – recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 60:1

    Google Scholar 

  181. Centers for Disease Control and Prevention (CDC) (2013) Advisory Committee on Immunization Practices (ACIP) recommended immunization schedules for persons aged 0 through 18 years and adults aged 19 years and older – United States, 2013. MMWR Surveill Summ 62(Suppl 1):1

    Google Scholar 

  182. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER (2007) Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56:1

    PubMed  Google Scholar 

  183. Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG et al (2007) Gynecologic Cancer Advisory Group, Garcia F. American cancer society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 57:7

    Article  PubMed  Google Scholar 

  184. www.who.int/wer. Accessed 8 Dec 2017

  185. Giuliano AR, Palefsky JM, Goldstone S et al (2011) Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 364:401

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  186. Kim JJ (2010) Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis 10:845

    Article  PubMed  PubMed Central  Google Scholar 

  187. Centers for Disease Control and Prevention (CDC) (2011) Recommendations on the use of quadrivalent human papillomavirus vaccine in males-advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep. 2011 60:1705

    Google Scholar 

  188. Centers for Disease Control and Prevention (CDC) (2010) FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 59:626

    Google Scholar 

  189. Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G (2009) A pooled analysis of contin- ued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2:868

    Article  Google Scholar 

  190. Ferlay J, Shin HR, Bray F et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917

    Article  CAS  PubMed  Google Scholar 

  191. Termrungruanglert W, Havanond P, Khemapech N, Lertmaharit S, Pongpanich S, Khorprasert C, Taneepanichskul S (2012) Cost and effectiveness evaluation of prophylactic HPV vaccine in developing countries. Value Health 15:S29–S34

    Article  PubMed  Google Scholar 

  192. From the Centers for Disease Control and Prevention (1993) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 269:729

    Article  Google Scholar 

  193. Maiman M, Fruchter RG, Clark M, Arrastia CD, Matthews R, Gates EJ (1997) Cervical cancer as an AIDS-defining illness. Obstet Gynecol 89:76

    Article  CAS  PubMed  Google Scholar 

  194. Ahdieh L, Klein RS, Burk R, Cu-Uvin S, Schuman P, Duerr A, Safaeian M, Astemborski J, Daniel R, Shah K (2001) Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis 184:682–690

    Article  CAS  PubMed  Google Scholar 

  195. Harris TG, Burk RD, Palefsky JM, Massad LS, Bang JY, Anastos K, Minkoff H, Hall CB, Bacon MC, Levine AM, Watts DH, Silverberg MJ, Xue X, Melnick SL, Strickler HD (2005) Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. JAMA 293:1471–1476

    Article  CAS  PubMed  Google Scholar 

  196. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR et al (2005) Prophylactic quadri- valent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6:271–278

    Article  PubMed  Google Scholar 

  197. Fruchter RG, Maiman M, Sedlis A, Bartley L, Camilien L, Arrastia CD (1996) Multiple recurrences of cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Obstet Gynecol 87:338

    Article  CAS  PubMed  Google Scholar 

  198. Marnitz S, Schmittel A, Bolbrinker J, Schmidt FP, Fons G, Kalache K, Schneider A, Köhler C (2009) The therapeutic management of a twin pregnancy complicated by the presence of cervical cancer, following laparoscopic staging and chemotherapy, with an emphasis on cisplatin concentrations in the fetomaternal compartments amnion fluid, umbilical cord, and maternal serum. Fertil Steril 92:e1–e4

    Article  Google Scholar 

  199. Marnitz S, Köhler C, Oppelt P, Schmittel A, Favero G, Hasenbein K, Schneider A, Markman M (2010) Cisplatin application in pregnancy: first in vivo analysis of 7 patients. Oncology 79:72–77

    Article  CAS  PubMed  Google Scholar 

  200. National Comprehensive Cancer Network (2012) Cervical cancer, version 1. Available online http://www.nccn.org/professionals/physician_gls/PDF/cervical.pdf

  201. Morice P, Uzan C, Gouy S, Verschraegen C, Haie-Meder C (2012) Gynaecological cancers in pregnancy. Lancet 3379:558–569

    Article  Google Scholar 

  202. Morice P, Narducci F, Mathevet P et al (2009) On the behalf of the French Working Group on Gynecological Cancers in Pregnancy, Société Française D’Oncologie Gynécologique (SFOG), Société Française de Chirurgie Pelvienne (SFCP), and the Collège National des Gynécologues Obstétriciens Français (CNGOF). Int J Gynecol Cancer 19:1638–1641

    Article  PubMed  Google Scholar 

  203. Plante M, Renaud MC, Hoskins IA, Roy M (2005) Vaginal radical trachelectomy: a valuable fertility- preserving option in the management of early-stage cervical cancer. A series of 50 pregnancies and review of the literature. Gynecol Oncol 98:3–10

    Article  PubMed  Google Scholar 

  204. Bleyer A, O’Leary M, Barr R, Ries L (eds) (2006) Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975–2000. National Cancer Institute, NIH Pub. No. 06-5767. Bethesda

    Google Scholar 

  205. Kardakis S (2012) Fertility-preserving surgery in patients with early stage cervical carcinoma. ISRN Oncol. Review of fertility-preserving surgery in cervical carcinoma

    Google Scholar 

  206. Wright JD, Nathavith Arana R, Lewin SN, Sun X, Deutsch I, Burke WM, Herzog TJ (2010) Fertility-conserving surgery for young women with stage IA1 cervical cancer: safety and access. Obstet Gynecol 115:585–590

    Article  PubMed  Google Scholar 

  207. Arbyn M, Kyrgiou M, Simoens C, Raifu AO, Koliopoulos G, Martin-Hirsch P, Prendiville W, Paraskevaidis E (2008) Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 337:a1284

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  208. Rob L, Charvat M, Robova H, Pluta M, Strnad P, Hrehorcak M, Skapa P (2007) Less radical fertility-sparing surgery than radical trachelectomy in early cervical cancer. Int J Gynecol Cancer 17:304–310

    Article  CAS  PubMed  Google Scholar 

  209. Milliken DA, Shepherd JH (2008) Fertility preserving surgery for carcinoma of the cervix. Curr Opin Oncol 20:575–580

    Article  PubMed  Google Scholar 

  210. Jolley JA, Battista L, Wing DA (2007) Management of pregnancy after radical trachelec tomy: case reports and systematic review of the literature. Am J Perinatol 24:531–539

    Article  PubMed  Google Scholar 

  211. Boss EA, van Golde RJ, Beerendonk CC, Massuger LF (2005) Pregnancy after radical trachelectomy: a real option? Gynecol Oncol 99(Suppl 1):S152–S156. 152

    Article  CAS  PubMed  Google Scholar 

  212. Dursun P, Ayhan A, Yanik FB, Kuşçu E (2009) Ovarian transposition for the preservation of ovarian function in young patients with cervical carcinoma. Eur J Gynaecol Oncol 30:13–15

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Drug Development Unit and West Wing Clinical Research Centre, The Royal Marsden Foundation Trust, Sutton, UK

    Alvaro Henrique Ingles Garces

  2. INCA (Brazilian National Cancer Institute), Rio de Janeiro, Brazil

    Andreia Cristina de Melo

  3. Grupo Oncoclínicas do Brasil, São Paulo, Brazil

    Andreia Cristina de Melo & Mariane Sousa Fontes Dias

  4. Brazilian Group of Gynecologic Oncology, EVA Group, Rio de Janeiro, Brazil

    Andreia Cristina de Melo, Eduardo Paulino & Angélica Nogueira-Rodrigues

  5. Department of Gynaecology Oncology, Brazilian National Cancer Institute, Rio de Janeiro, Brazil

    Eduardo Paulino

  6. Federal University of Minas Gerais, Belo Horizonte, Brazil

    Angélica Nogueira-Rodrigues

  7. Dom Oncologia, Divinópolis, Brazil

    Angélica Nogueira-Rodrigues

  8. Brazilian National Cancer Institute, Rio de Janeiro, Brazil

    Rachele Grazziotin, Márcio Lemberg Reisner, Gustavo Guitmann & Gustavo Iglesias

  9. Department of Gynaecology Oncology, Americas Medical City, Rio de Janeiro, Brazil

    Gustavo Guitmann

  10. Society Gynecologic Oncology, Chicago, IL, USA

    Gustavo Guitmann

  11. President Oncoclínicas Institute, Rio de Janeiro, Brazil

    Carlos Gil Ferreira

Authors
  1. Alvaro Henrique Ingles Garces
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreia Cristina de Melo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eduardo Paulino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Angélica Nogueira-Rodrigues
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rachele Grazziotin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Márcio Lemberg Reisner
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mariane Sousa Fontes Dias
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Gustavo Guitmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Gustavo Iglesias
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Carlos Gil Ferreira
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Medical Oncology, Federal University of São Paulo (UNIFESP) & Hospital Israelita Albert Einstein, São Paulo, Brazil, Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal

    Ramon Andrade De Mello

  2. Oncology Department, Henry Dunant Hospital Center, Athens, Greece

    Giannis Mountzios

  3. Department of Biomedical Sciences and Medicine, Universidade do Algarve, Faro, Portugal

    Álvaro A. Tavares

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Garces, A.H.I. et al. (2019). Approach and Management of Cervical Cancer. In: De Mello, R., Mountzios, G., Tavares, Á. (eds) International Manual of Oncology Practice. Springer, Cham. https://doi.org/10.1007/978-3-030-16245-0_23

Download citation

Publish with us

Policies and ethics

Search

Navigation